|
| |
| | | 58271 | | 28.05.2009 | | Novartis Pharma Schweiz AG | | | | | | | 27.05.2019 | | | | | | 08.08. | | 08.12.2016 | | 08.08. | | IPro |
| | Seq.-nr. | Préparation | Description | Forme galénique | Classe d'ATC | |
|---|
| 01 | Optaflu | Injektionssuspension | Suspension injectable () + (Vaccinum Influenzae Inactivatum ex Corticis Antigeniis Praeparatum (Cellulae Mdck) 2015/2016 0 ) | J07BB02 | | | 02 | Optaflu | Injektionssuspension | Suspension injectable (Haemagglutininum Influenzae a (H1N1) (Virus-Stamm A/california/7/2009 (H1N1)-Like: Reassortant Virus A/brisbane/10/2010) 15 µg, Haemagglutininum Influenzae a (H3N2) (Virus-Stamm A/texas/50/2012 (H3N2)-Like: Reassortant Virus nymc X-223a) 15 µg, Haemagglutininum Influenzae b (Virus-Stamm B/massachusetts/2/2012) 15 µg) | J07BB02 | | | 03 | Optaflu | Injektionssuspension | Suspension injectable (Haemagglutininum Influenzae a (H1N1) (Virus-Stamm A/california/7/2009 (H1N1)-Like: A/brisbane/10/2010) 15 µg, Haemagglutininum Influenzae a (H3N2) (Virus-Stamm A/switzerland/9715293/2013 (H3N2)-Like: A/south Australia/55/2014) 15 µg, Haemagglutininum Influenzae b (Virus-Stamm B/phuket/3073/2013-Like: B/utah/9/2014) 15 µg) | J07BB02 | |
|
|
|
